Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: A meta-analysis of 14 randomized controlled trials

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1479-1488

  Wang, Long ^a   Xu, Yan Li ^a   Zhang, Xiu Qun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Doxorubicin; Lenalidomide; Meta analysis; Multiple myeloma; Randomized controlled trials; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COCHRANE LIBRARY; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAZARD RATIO; HUMAN; INFECTION; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT RESPONSE; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; MORTALITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DOXORUBICIN; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84903469341     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.838232     Document Type: Article

References (21)

1. Danylesko I, Beider K, Shimoni A, et al. Monoclonal antibodybasedimmunotherapy for multiple myeloma. Immunotherapy 2012 ; 9 : 919-938.
2. Chanan-Khan A A, Giralt S. Importance of achieving a completeresponse in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010 ; 15 : 2612-2624.
3. Dingli D, Pacheco J M, Nowakowski G S, et al. Relationship betweendepth of response and outcome in multiple myeloma. J Clin Oncol 2007 ; 31 : 4933-4937.
4. Altman DG, Schulz KF, Moher D, et al. Th e revised CONSORTstatement for reporting randomized trials: explanation and elaboration.Ann Intern Med 2001 ; 8 : 663-694.
5. Juni P, Altman DG, Egger M. Systematic reviews in health care:assessing the quality of controlled clinical trials. BMJ 2001 ; 323 : 42-46.
6. Blade J, Samson D, Reece D, et al. Criteria for evaluating diseaseresponse and progression in patients with multiple myeloma treatedby high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT. European Group for Blood andMarrow Transplant. Br J Haematol 1998 ; 102 : 1115-1123.
7. National Cancer Institute: Common terminology criteriafor adverse events, v3.0. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-v3.0
8. Mateos M V, Oriol A, Martinez-Lopez J, et al. Maintenance therapywith bortezomib plus thalidomide or bortezomib plus prednisone inelderly multiple myeloma patients included in the GEM2005MAS65trial. Blood 2012 ; 120 : 2581-2588.
9. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantationtherapy in multiple myeloma: a randomized phase 3PETHEMA/GEM study. Blood 2012 ; 120 : 1589-1596.
10. Garderet L, Iacobelli S, Moreau P, et al. Superiority of thetriple combination of bortezomib-thalidomide-dexamethasone overthe dual combination of thalidomide-dexamethasone in patientswith multiple myeloma progressing or relapsing after autologoustransplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trialfrom the Chronic Leukemia Working Party of the European Group forBlood and Marrow Transplantation. J Clin Oncol 2012 ; 30 : 2475-2482.
11. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib- thalidomidedexamethasoneis superior to thalidomide-dexamethasone asconsolidation therapy after autologous hematopoietic stem celltransplantation in patients with newly diagnosed multiple myeloma.Blood 2012 ; 120 : 9-19.
12. Morabito F, Gentile M, Mazzone C, et al. Safety and effi cacyof bortezomib-melphalan-prednisone-thalidomide followed bybortezomib-thalidomide maintenance (VMPT-VT) versus bortezomibmelphalan-prednisone (VMP) in untreated multiple myeloma patientswith renal impairment. Blood 2011; 118: 5759-5766.
13. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plusdexamethasone versus reduced-dose bortezomib, thalidomide plusdexamethasone as induction treatment before autologous stemcell transplantation in newly diagnosed multiple myeloma. Blood2011 ; 118 : 5752-5758, 5982.
14. Chen RA, Tu Y, Cao Y, et al. Bortezomib-dexamethasone orvincristine-doxorubicin-dexamethasone as induction therapy followedby thalidomide as maintenance therapy in untreated multiple myelomapatients. J Int Med Res 2011; 39: 1975-1984.
15. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalanprednisone- thalidomide followed by maintenance with bortezomibthalidomidecompared with bortezomib-melphalan-prednisone forinitial treatment of multiple myeloma: a randomized controlled trial.J Clin Oncol 2010 ; 28 : 5101-5109.
16. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomideplus dexamethasone compared with thalidomide plus dexamethasoneas induction therapy before, and consolidation therapy after, doubleautologous stem-cell transplantation in newly diagnosed multiplemyeloma: a randomised phase 3 study. Lancet 2010 ; 376 : 2075-2085.
17. Mateos M V, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, andprednisone as induction therapy followed by maintenance treatmentwith bortezomib and thalidomide versus bortezomib and prednisonein elderly patients with untreated multiple myeloma: a randomisedtrial. Lancet Oncol 2010 ; 11 : 934-941.
18. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previouslyuntreated multiple myeloma. Blood 2012 ; 119 : 4375-4382.
19. Sonneveld P, Schmidt-Wolf I G, van der Holt B, et al. Bortezomibinduction and maintenance treatment in patients with newly diagnosedmultiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012 ; 30 : 2946-2955.
20. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylatedliposomal doxorubicin and bortezomib is highly eff ective in patientswith recurrent or refractory multiple myeloma who received priorthalidomide/lenalidomide therapy. Cancer 2008; 112: 1529-1537.
21. Orlowski R Z, Nagler A, Sonneveld P, et al. Randomized phase IIIstudy of pegylated liposomal doxorubicin plus bortezomib comparedwith bortezomib alone in relapsed or refractory multiple myeloma:combination therapy improves time to progression. J Clin Oncol2007 ; 25 : 3892-3901.